Bone Therapeutics (Belgium) is a cell therapy biotech working on bone fracture repair which has now extended its collaboration with Kasios (France), to develop next-generation bone disease therapy with 3D-Bioprinting technology.
The current standard-of-care in the Bones field involves major surgeries and (consequently) long recovery time. Bone Therapeutics is, therefore, developing a range of regenerative products containing osteoblasts (bone-forming cells), which can be injected with minimal invasiveness.
Preob, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIb/III clinical studies for two indications: osteonecrosis (for which it has FDA Orphan Drug Designation), non-union fractures, and phase II trials for severe osteoporosis.
Allob on the other hand is an allogeneic “off-the-shelf” cell product made from adult bone marrow donors. It is in phase I/IIa trials for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine.
Inducing Spinal fusion is considered to be the gold standard for treating a broad spectrum of degenerative spine disorders,